U.S. Stock News

Iovance Biotherapeutics stock has delivered a steep 217.1% return year to date, yet current checks point to shares trading on the expensive side when compared with fundamental metrics. For investors, that mix of strong momentum and a market multiple that screens as overvalued raises questions about how much upside is already reflected in the price. The year to date gain of 217.1% suggests expectations for Iovance Biotherapeutics have reset sharply higher and now carry a lot more...

Kroger stock has delivered a 36.9% total return over the past five years, yet with the shares down 19.9% over the last year and the valuation checks pointing to value in several areas, investors are weighing whether the current price still offers a reasonable entry point or is closer to fully reflecting the fundamentals. A 36.9% return over five years suggests Kroger has rewarded patient shareholders. This raises the question of how much of that progress is already reflected in today’s share...

Sherwin-Williams has delivered a 33.2% gain over the past three years, yet the stock now trades on earnings multiples that lean expensive, while a Discounted Cash Flow (DCF) intrinsic value estimate points to a price that is close to fair value. With the broader valuation checks also coming in weak, investors are weighing recent returns against a thinner margin of safety. The 33.2% return over three years suggests Sherwin-Williams has rewarded patient shareholders, which can make fresh entry...

Robert Half stock has gained 59.3% year to date, yet its valuation checks send mixed signals, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) model pointing to meaningful upside while market based multiples suggest the shares are on the expensive side. Year to date, Robert Half is up 59.3%. This puts more focus on whether the current price still leaves enough margin between the market value and the underlying cash flow potential. Expectations for the company’s ability...

The recent testing of Claude designed proteins, which bound to 14 of 15 targets in work involving Twist Bioscience (TWST), has drawn fresh attention to how AI could influence end to end drug development. See our latest analysis for Twist Bioscience. Twist Bioscience’s share price has reacted strongly to the Claude protein news and wider interest in AI driven drug discovery, with a 30 day share price return of 62.82% and a year to date share price return of 339.61%, while the 1 year total...

Why Maravai LifeSciences Holdings Stock Is Back in Focus After Q2 2026 Earnings Maravai LifeSciences Holdings (MRVI) moved back onto investor watchlists after reporting second quarter 2026 results, with higher sales, a smaller net loss and reiterated full year revenue guidance. See our latest analysis for Maravai LifeSciences Holdings. Maravai LifeSciences Holdings has seen strong momentum build around these results, with a 25.78% 1 day share price return and a 112.35% year to date share...

Recent commentary around Hut 8 (NasdaqGS:HUT) focuses on its push into large AI focused data center campuses and long term contracted capacity, while regulatory reviews in Texas raise questions about how quickly related cash flows might materialize. See our latest analysis for Hut 8. Hut 8’s latest US$82.08 share price comes after a 1-day share price return of 1.60%. However, the 7-day and 30-day share price returns are down 9.57% and 18.68% respectively. This recent weakness contrasts with a...

Old Dominion Freight Line stock has delivered a 47.0% gain over the past five years, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to an overvalued picture rather than a clear bargain. A 47.0% return over five years suggests Old Dominion Freight Line has rewarded patient shareholders, which naturally raises the bar for what counts as good value today. Future cash flow growth and margin resilience can support the current share price. Any...

Amkor Technology stock has surged over the past year, yet its current US$50.89 share price still screens as cheap, with both the Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples pointing to undervaluation. Amkor Technology has returned 123.2% over the past year, which puts fresh focus on whether the current valuation still leaves room for further upside. The multi year packaging agreement with Nvidia can support expectations for future cash flows. However, the...

In early August 2026, The Travelers Companies, Inc. expanded its Board from eight to nine directors and appointed former Dun & Bradstreet and Black Knight leader Anthony Jabbour as a director, assigning him to the Audit and Risk Committees. By adding a director with deep data, analytics, and fintech experience, Travelers is reinforcing its focus on information-driven risk assessment, financial oversight, and technology investment. We’ll now examine how Anthony Jabbour’s appointment to...

H&R Block (HRB) is back in focus after its latest quarterly and full year earnings update, which highlighted higher revenue and earnings per share, along with new guidance, an ongoing buyback and a higher dividend. See our latest analysis for H&R Block. The latest earnings release and guidance appear to have reset expectations around H&R Block, with a 30 day share price return of 25.3% and a 90 day share price return of 37.9%, while the 5 year total shareholder return of 141.49% points to a...

Record US national debt of about US$40t, rising interest costs and fresh spending linked to the war in Iran are reshaping where money flows in markets. Some stocks could feel squeezed by higher financing costs, while others may gain from shifting federal priorities. This article examines 3 U.S. Defense and Aerospace Stocks screener companies that appear especially exposed to these forces and explains what that might mean for your portfolio. The three U.S. defense and aerospace stocks covered...

Advanced Drainage Systems, Inc. reported first-quarter 2026 results showing higher sales and earnings year over year, confirmed its fiscal 2027 net sales guidance range of US$3.35 billion to US$3.55 billion, and previously approved a quarterly cash dividend of US$0.20 per share, an 11% increase over the prior year amount, paid on September 15, 2026. The company also completed a sizeable share repurchase program totaling 10,564,000 shares for US$1,179.44 million, alongside increasing its...

Inspire Medical Systems was added in the past week to the Zacks Rank #1 (Strong Buy) list, after analysts lifted their current-year earnings consensus by very large over the last 60 days for its minimally invasive obstructive sleep apnea therapy business. This sharp upward revision in earnings forecasts highlights how quickly sentiment can shift for specialized medical technology firms when analysts reassess profit potential. Next, we’ll examine how Inspire’s inclusion in the Zacks Rank #1...

GE Vernova (GEV) has come under pressure after a weaker U.S. industrial production report triggered a sector-wide pullback in industrial stocks, even as its AI driven nuclear fuel tracking work with SHINE draws attention. See our latest analysis for GE Vernova. Despite the macro driven pullback, GE Vernova still carries strong momentum, with a 45.31% year to date share price return and a 63.70% total shareholder return over the past year. If the recent focus on nuclear fuel and grid...

In August 2026, National Vision Holdings reported second-quarter revenue of US$498.81 million and net income of US$12.42 million, raised its full-year adjusted operating income outlook, slightly narrowed its fiscal 2026 revenue guidance range to US$2.04–US$2.08 billion, and completed a US$20 million repurchase of 1,200,000 shares. The results highlight margin improvement tied to higher-value customers, premium product attachment, and a newly implemented e-commerce platform that management...

Olin (OLN) drew fresh attention on August 12, 2026 after filing a US$95.4 million shelf registration covering 5,000,000 common shares tied to an employee stock ownership plan offering. See our latest analysis for Olin. At a share price of US$18.71, Olin has seen its 30 day share price return fall 15.64% and its 90 day share price return decline 28.09%, while the 3 year total shareholder return is down 64.38%. This points to fading momentum despite the recent ESOP related shelf registration...

Compañía de Minas BuenaventuraA (BVN) is back in focus as investors track the planned ramp up of its San Gabriel gold project and react to softer peer results that exposed sensitivity to volumes and pricing. See our latest analysis for Compañía de Minas BuenaventuraA. At a latest share price of $33.98, Compañía de Minas BuenaventuraA has a 30 day share price return of 13.04% and a year to date share price return of 18.85%. The 1 year total shareholder return of 92% and 5 year total...

Earlier this month, Kroll Bond Rating Agency affirmed Hercules Capital, Inc.’s investment grade corporate and credit rating at BBB+, citing its diversified investment portfolio, solid operating history, appropriate leverage metrics, and robust risk management. This affirmation underlines external confidence in Hercules Capital’s ability to manage risk and maintain access to funding across a diversified capital structure. We’ll now examine how the reaffirmed BBB+ investment grade rating could...

Manchester United recently accelerated its squad rebuild with multiple midfield signings, pursued a deal for Brighton’s Carlos Baleba, returned to the Champions League, and secured land for a planned 100,000-seater stadium. Together, these footballing and infrastructure moves highlight how the club is trying to deepen on-pitch competitiveness while expanding long-term matchday and broadcasting revenue potential. We’ll now examine how Manchester United’s planned 100,000-seater stadium shapes...

Sotera Health (SHC) is back on investor watch after reporting second quarter results that exceeded analyst expectations, with higher revenue and net income drawing fresh attention to the stock’s recent share price gains. See our latest analysis for Sotera Health. At a share price of US$19.00, Sotera Health has seen a 20.94% 90 day share price return and a 16.56% 1 year total shareholder return, which suggests recent momentum has been building following the Q2 earnings beat and the August...

In August 2026, Peloton Interactive, Inc. reported fourth-quarter revenue of US$607.7 million and full-year 2026 revenue of US$2.45 billion, alongside a shift from a prior net loss to net income of US$63.2 million and positive earnings per share. At the same time, Peloton issued guidance for fiscal 2027 that points to essentially flat first-quarter revenue and a modest full-year revenue decline, setting up a contrast between recent profitability gains and management’s more cautious sales...

American Assets Trust (AAT) is back on investors’ radar after recent trading left the stock down about 10% over the past month while still showing a gain over the past 3 months. See our latest analysis for American Assets Trust. At a latest share price of $22.80, American Assets Trust shows a 30 day share price return that is down 9.74%. However, its year to date share price return and 1 year total shareholder return of 21.41% and 23.56% respectively indicate momentum that has broadly held up...

Rosen Law Firm recently began investigating potential securities claims on behalf of Disc Medicine shareholders, following the FDA’s February 2026 Complete Response Letter rejecting approval of the company’s bitopertin program and requesting additional evidence. This combination of regulatory setback and legal scrutiny raises fresh questions about Disc Medicine’s prior communications around bitopertin’s prospects and supporting data. We’ll now examine how the FDA’s Complete Response Letter...